Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MITF | O75030 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9674402 | 0.76 | HTT (0.55) | CYP3A4CYP1A2CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL1414572 | 0.75 | — | — | |
| SCHEMBL27984511 | 0.75 | KMT2A (0.45) | ALDH1A1SMN1; SMN2HTTMITFPOLB | |
| SCHEMBL31104020 | 0.73 | HTT (0.31) | ALDH1A1SMN1; SMN2HTTMITFPOLB | |
| SCHEMBL9727068 | 0.73 | HTT (0.41) | CYP3A4CYP1A2CYP2D6CASP3ALDH1A1 | |
| SCHEMBL25342529 | 0.72 | NLRP3 (0.47) | ALDH1A1SMN1; SMN2HTTLMNAMITF | |
| SCHEMBL7376931 | 0.72 | CASP3 (0.38) | CYP3A4CYP1A2CYP2D6CASP3ALDH1A1 | |
| SCHEMBL2720779 | 0.72 | RAB9A (0.33) | CYP3A4CASP3ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL27266543 | 0.71 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2HTTLMNAMITF | |
| SCHEMBL1367696 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071411-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-03-15 | — | — | US | claimed |
| US-20130101508-A9 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-04-25 | — | — | US | claimed |
| US-20120237445-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-20 | — | — | US | claimed |
| CN-102458396-A | Stabilization of radiopharmaceutical compositions using ascorbic acid | LANTHEUS MEDICAL IMAGING INC | 2012-05-16 | — | — | CN | claimed |
| EP-2419096-A2 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | Lantheus Medical Imaging, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| WO-2010120368-A2 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2010-10-21 | — | — | WO | claimed |
| CN-107261159-B | Stabilization of radiopharmaceutical compositions using ascorbic acid | 兰休斯医疗成像公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20200222562-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| EP-2419096-B1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20180071411-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-9687571-B2 | Stabilization of radiopharmaceutical compositions using ascorbic acid | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20130101508-A9 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120237445-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| CN-102458396-A | Stabilization of radiopharmaceutical compositions using ascorbic acid | LANTHEUS MEDICAL IMAGING INC | 2012-05-16 | — | — | CN | disclosed |
| EP-2419096-A2 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | Lantheus Medical Imaging, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120368-A2 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | LANTHEUS MEDICAL IMAGING, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222562-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | TTPA, PROC, RBP1 | CYP3A4 1977/4885CYP1A2 1304/4885CYP2D6 447/4885 |
| US-20180071411-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | TTPA, PROC, RBP1 | CYP3A4 1977/4885CYP1A2 1304/4885CYP2D6 447/4885 |
| US-20120237445-A1 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | TTPA, PROC, RBP1 | CYP3A4 1977/4885CYP1A2 1304/4885CYP2D6 447/4885 |
| US-20130101508-A9 | STABILIZATION OF RADIOPHARMACEUTICAL COMPOSITIONS USING ASCORBIC ACID | TTPA, PROC, RBP1 | CYP3A4 1977/4885CYP1A2 1304/4885CYP2D6 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.